glp 1 oral novo nordisk Nordisk's Wegovy Pill Becomes First GLP-1 Available in U.S Novo applies to FDA for

Journal of Diabetes and Metabolism

compared ALT-801 (another dual GLP-1/GCG receptor agonist), semaglutide and elafibranor in AMLN diet NAFLD mouse model to validate the beneficial effects of GLP-1/GCG dual agonism in NAFLD hepatic outcomes

Therefore, the clinical effects of LA should be examined in the early stage of AFLD, or a higher dose of LA should be considered

The two peptides have separate FDA concerns: FDA flagged CJC-1295 for limited clinical data and serious adverse events including increased heart rate and systemic vasodilatory reaction

dosing If concern for active thiamine deficiency: 500 mg IV q8hr

Storage: To maintain the peptides effectiveness over time, containers must be kept tightly closed